Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models-Reference-Cited by-同舟云学术

Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models

Published:2019-01-04 Issue:1 Volume:5 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Elliott Mark¹^ORCID,Favre-Guilmard Christine²,Liu Sai Man¹^ORCID,Maignel Jacquie²^ORCID,Masuyer Geoffrey³^ORCID,Beard Matthew¹^ORCID,Boone Christopher⁴,Carré Denis²,Kalinichev Mikhail²,Lezmi Stephane²,Mir Imran¹^ORCID,Nicoleau Camille²^ORCID,Palan Shilpa¹^ORCID,Perier Cindy²^ORCID,Raban Elsa²^ORCID,Zhang Sicai⁴,Dong Min⁴^ORCID,Stenmark Pål³⁵^ORCID,Krupp Johannes¹²^ORCID

Affiliation:

1. Ipsen Bioinnovation, 102 Park Drive, Milton Park, Abingdon OX14 4RY, UK.

2. Ipsen Innovation, 5 Avenue du Canada, 91940 Les Ulis, France.

3. Department of Biochemistry and Biophysics, Stockholm University, Stockholm SE-106 91, Sweden.

4. Department of Urology, Boston Children’s Hospital, Department of Microbiology and Immunobiology and Department of Surgery, Harvard Medical School, Boston, MA 02115, USA.

5. Department of Experimental Medical Science, Lund University, 221 00 Lund, Sweden.

Abstract

We report the preclinical characterization of two engineered botulinum neurotoxin serotype B proteins with significant therapeutic potential.

Funder

NIH Office of the Director

Burroughs Wellcome Fund

Wenner-Gren Foundation

Ipsen Biopharmaceuticals

Swedish Research Council for Health, Working Life and Welfare

Swedish Cancer Society

Publisher

American Association for the Advancement of Science (AAAS)